| Literature DB >> 30698984 |
Katsuhiko Mitachi1, Shou M Kurosu1, Shakiba Eslamimehr1, Maddie R Lemieux1, Yoshimasa Ishizaki2, William M Clemons3, Michio Kurosu1.
Abstract
We have explored a method to convert a muraymycin biosynthetic intermediate 3 to an anticancer drug lead 2 for in vivo and thorough preclinical studies. Cu(OAc)2 forms a stable complex with the amide 4 and prevents electrophilic reactions at the 2-((3-aminopropyl)amino)acetamide moiety. Under the present conditions, the desired 5″-primary amine was selectively protected with (Boc)2O to yield 6. The intermediate 6 was converted to 2 in two steps with 90% yield.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30698984 PMCID: PMC6447083 DOI: 10.1021/acs.orglett.8b03716
Source DB: PubMed Journal: Org Lett ISSN: 1523-7052 Impact factor: 6.005